These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 22034888)

  • 1. Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair-proficient and -deficient colorectal cancers.
    Zlobec I; Minoo P; Terracciano L; Baker K; Lugli A
    Histopathology; 2011 Sep; 59(3):482-95. PubMed ID: 22034888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mismatch repair status in patients with primary operable colorectal cancer: associations with the local and systemic tumour environment.
    Park JH; Powell AG; Roxburgh CS; Horgan PG; McMillan DC; Edwards J
    Br J Cancer; 2016 Mar; 114(5):562-70. PubMed ID: 26859693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of β-2-microglobulin expression in colorectal cancers stratified by mismatch repair status.
    Koelzer VH; Baker K; Kassahn D; Baumhoer D; Zlobec I
    J Clin Pathol; 2012 Nov; 65(11):996-1002. PubMed ID: 22859396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of hMLH1 or hMSH2 expression as a stage-dependent prognostic factor in sporadic colorectal cancers.
    Park JW; Chang HJ; Park S; Kim BC; Kim DY; Baek JY; Kim SY; Oh JH; Choi HS; Park SC; Jeong SY
    Ann Surg Oncol; 2010 Nov; 17(11):2839-46. PubMed ID: 20549564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor buds show reduced expression of laminin-5 gamma 2 chain in DNA mismatch repair deficient colorectal cancer.
    Shinto E; Baker K; Tsuda H; Mochizuki H; Ueno H; Matsubara O; Foulkes WD; Jass JR
    Dis Colon Rectum; 2006 Aug; 49(8):1193-202. PubMed ID: 16773493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients.
    Frey DM; Droeser RA; Viehl CT; Zlobec I; Lugli A; Zingg U; Oertli D; Kettelhack C; Terracciano L; Tornillo L
    Int J Cancer; 2010 Jun; 126(11):2635-43. PubMed ID: 19856313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases.
    Bendardaf R; Lamlum H; Ristamäki R; Korkeila E; Syrjänen K; Pyrhönen S
    Acta Oncol; 2008; 47(6):1046-53. PubMed ID: 17943475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
    Ohrling K; Edler D; Hallström M; Ragnhammar P
    Acta Oncol; 2010 Aug; 49(6):797-804. PubMed ID: 20307245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of association between deficient mismatch repair expression and outcome in endometrial carcinomas of the endometrioid type.
    Ruiz I; Martín-Arruti M; Lopez-Lopez E; Garcia-Orad A
    Gynecol Oncol; 2014 Jul; 134(1):20-3. PubMed ID: 24814467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An alternative pathway in colorectal carcinogenesis based on the mismatch repair system and p53 expression in Korean patients with sporadic colorectal cancer.
    Kim HR; Kim HC; Yun HR; Kim SH; Park CK; Cho YB; Yun SH; Lee WY; Chun HK
    Ann Surg Oncol; 2013 Nov; 20(12):4031-40. PubMed ID: 22732839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
    Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
    Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
    Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mismatch repair protein expression in Amsterdam II criteria-positive patients in Taiwan.
    Chen JR; Chiang JM; Changchien CR; Chen JS; Tang RP; Wang JY
    Br J Surg; 2008 Jan; 95(1):102-10. PubMed ID: 18064717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study.
    Kloor M; Huth C; Voigt AY; Benner A; Schirmacher P; von Knebel Doeberitz M; Bläker H
    Lancet Oncol; 2012 Jun; 13(6):598-606. PubMed ID: 22552011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mismatch repair pathway: molecules, functions, and role in colorectal carcinogenesis.
    Sameer AS; Nissar S; Fatima K
    Eur J Cancer Prev; 2014 Jul; 23(4):246-57. PubMed ID: 24614649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients.
    Lugli A; Vlajnic T; Giger O; Karamitopoulou E; Patsouris ES; Peros G; Terracciano LM; Zlobec I
    Hum Pathol; 2011 Dec; 42(12):1833-40. PubMed ID: 21664647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical utility of the local inflammatory response in colorectal cancer.
    Richards CH; Roxburgh CS; Powell AG; Foulis AK; Horgan PG; McMillan DC
    Eur J Cancer; 2014 Jan; 50(2):309-19. PubMed ID: 24103145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routine testing for mismatch repair deficiency in sporadic colorectal cancer is justified.
    Ward RL; Turner J; Williams R; Pekarsky B; Packham D; Velickovic M; Meagher A; O'Connor T; Hawkins NJ
    J Pathol; 2005 Dec; 207(4):377-84. PubMed ID: 16175654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes.
    Williams DS; Mouradov D; Jorissen RN; Newman MR; Amini E; Nickless DK; Teague JA; Fang CG; Palmieri M; Parsons MJ; Sakthianandeswaren A; Li S; Ward RL; Hawkins NJ; Faragher I; Jones IT; Gibbs P; Sieber OM
    Gut; 2019 Mar; 68(3):465-474. PubMed ID: 29382774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active immunosurveillance in the tumor microenvironment of colorectal cancer is associated with low frequency tumor budding and improved outcome.
    Koelzer VH; Dawson H; Andersson E; Karamitopoulou E; Masucci GV; Lugli A; Zlobec I
    Transl Res; 2015 Aug; 166(2):207-17. PubMed ID: 25797890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.